Compare Abrdn Physical Platinum Shares ETF (PPLT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs GeneDx Holdings Corp — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.23 (market cap $1.93B), while GeneDx Holdings Corp trades at $67.73 (market cap $2.04B). The key difference: Abrdn Physical Platinum Shares ETF and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and GeneDx Holdings Corp for 19 Days on average.
| PPLT | WGS | |
|---|---|---|
Market Cap | $1.93B | $2.04B |
Volume | 2,947,556 | 659,215 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $167.51 |
52-Week Low | $13.73 | $34.51 |
Typical Hold Time | 42 Days | 19 Days |
Enterprise Value | — | $2.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
